1 Dec
2016

Director’s orders

Under threat from investors and generic rivals, pharma and biotech have become staunch opponents of the <em class="italic-light">inter partes</em> review regime. However, as they push for reform, they face a stiff challenge from the US Patent and Trademark Office and Congress